News Coverage - Parker Institute for Cancer Immunotherapy

Research
Network
News
About

Research
Network
- Research Institutions
  Our academic collaborators’ seminal contributions push the field forward
- Directory
  Our constellation of renowned thinkers and partners
- Strategic Partnerships
  The right collaborators across pharma, biotech and nonprofit
- Early Career Researchers
  The next generation of scientific leaders in cancer immunotherapy
News
- News Menu
  - The Latest
    Stories & Announcements
  - News Coverage
    PICI in the News
  - For Media
    Resources for Press
About
- Mission & Vision
  Develop breakthrough immune therapies to turn all cancers into curable diseases faster
- Leadership & Staff
  The driving force behind PICI’s research and operations
- Philanthropic Partners
  Transformative science requires visionary philanthropy
- Careers
  Join us. Change lives.

HemOnc Today

08.24.21

CRISPR gene editing may put universal T-cell therapy within reach

Read

KRON TV

08.13.21

V Foundation Wine Celebration Raises Millions to Support Cancer Research

Read

Finding Genius Podcast

07.21.21

A cure for cancer? Immunotherapy could be the key

Read

Endpoints News

07.20.21

Sean Parker-backed cell therapy startup ArsenalBio plucks Merck VP as new CSO

Read

Cure Today

06.17.21

Immunotherapy Options Around the Bend

Read

Precision Oncology

06.15.21

NanoString Technologies, Parker Institute for Cancer Immunotherapy Partner on Cell Therapy Project

Read

BioSpace

06.15.21

NanoString and Parker Institute for Cancer Immunotherapy Collaborate to Optimize Cell Therapies to Treat Cancer

Read

HemOnc Today

06.08.21

CAR-T with synthetic binder shows ‘very promising’ results in advanced multiple myeloma

Read

HemOnc Today

06.04.21

Gene-edited T-cell therapy shows ‘promising efficacy’ for rare sarcomas

Read

STAT+

04.28.21

Glowing tumor-munching cells, captured on video, show the promise of a new approach to CAR-T cancer therapy

Read

HemOnc Today

04.23.21

Tumor-infiltrating lymphocytes show ‘provocative’ response rates in advanced melanoma

Read

HemOnc Today

04.16.21

Product composition, immune biomarkers linked to CAR-T efficacy

Read